Evaluation and management of swallowing dysfunction following chemoradiation for head and neck cancer

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 15, Issue 2, 2007, Pages 130-133

  Nguyen, Nam P ^a   Smith, Herbert J ^b   Sallah, Sabah ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b VA North Texas Health Care System   (United States)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Chemoradiation; Dysphagia; Head and neck cancer; Swallowing therapy

Indexed keywords

AMIFOSTINE; CETUXIMAB; RITUXIMAB;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL EVALUATION; DIETITIAN; DISEASE SEVERITY; DRUG EFFICACY; DYSPHAGIA; HEAD AND NECK CANCER; HUMAN; MOLECULAR BIOLOGY; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOLOGIST; PATIENT CARE; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGIST; RADIATION DOSE; RADIATION INDUCED DYSPHAGIA; REVIEW; SPEECH THERAPY; SWALLOWING; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

CHEMOTHERAPY, ADJUVANT; DEGLUTITION DISORDERS; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY, ADJUVANT; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34247141878     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e32801da0e8     Document Type: Review

References (15)

1. Stenson KM, McCracken E, List M, et al. Swallowing function in patients with head and neck cancer prior to treatment. Arch Otolaryngol Head Neck Surg 2000; 126:371-377.
2. Logemann JA, Rademaker AW, Pauloski BR, et al. Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck 2006; 28:64-73. This prospective study demonstrates exacerbation of preexisting swallowing abnormalities with chemoradiation. The impact of the chemotherapy regimen is minimal on swallow function.
3. Chen HW, Chang YC, Lai YL, et al. Change of phasma transforming growth factor-β1 levels in nasopharyngeal carcinoma patients treated with concurrent chemo-radiotherapy. Jpn J Clin Oncol 2005; 35:427-432. This prospective study demonstrated a relationship between high levels of plasma TGF-β1 and mucositis severity during concurrent chemoradiation for nasopharyngeal carcinoma. This correlation suggests a role of TGF-β1 in normal tissue damage.
4. Felt D, Zavadova E, Pala M, Hozak P. Posttreatment plasma transforming growth factor beta 1 (TGF-beta1) level predicts for late morbidity in patients with advanced head and neck cancer. Neoplasma 2005; 52:393-397. This prospective study showed a relationship between high levels of plasma TGF-β1 level and severe late complications following concurrent chemoradiation for inoperable head and neck cancer.
5. Rosen A, Rhee TH, Kaufman R. Prediction of aspiration in patients with newly diagnosed untreated advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2001; 127:975-979.
6. Ott DJ, Hodge RG, Pikna LA, et al. Modified barium swallow: clinical and radiographic correlation and recommendations. Dysphagia 1996; 11:187-190.
7. Nguyen NP, Frank C, Moltz CC, et al. Impact of dysphagia on quality of life after treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 2005; 61:772-778. This retrospective surveyed patients who had MBS and responded to quality-of-life questionnaires. There was a correlation between poor quality of life and dysphagia severity observed on MBS during concurrent chemoradiation for head and neck cancer.
8. Nguyen NP, Moltz CC, Frank C, et al. Severity and duration of chronic dysphagia following treatment for head and neck cancer. Anticancer Res 2005; 25:2929-2934. This retrospective study showed long-term persistence of dysphagia on sequential MBS.
9. Nguyen NP, Moltz CC, Frank C, et al. Evolution of chronic dysphagia following treatment for head and neck cancer. Oral Oncol 2006; 42:374-380. This retrospective study showed significant esophageal stenosis in association with long-term dysphagia.
10. Sullivan CA, Jaklitsch MT, Haddad R, et al. Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck cancer. Laryngoscope 2004; 114:1924-1931.
11. Goguen LA, Posner MR, Norris CN, et al. Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer. Otolaryngol Head Neck Surg 2006; 134:916-922. This retrospective study demonstrated the efficacy of swallowing therapy if initiated early following treatment. Most of the patients were able to resume a normal diet and had their gastrostomy tubes removed 6-12months after treatment.
12. Nguyen NP, Moltz CC, Frank C, et al. Impact of swallowing therapy on aspiration rate following treatment for locally advanced head and neck cancer. Oral Oncol 2006; 21 August [Epub head of print]. This retrospective study emphasized the need to initiate swallowing therapy immediately following treatment if aspiration was diagnosed.
13. Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradioterapy for head and neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004; 60:1425-1439.
14. Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine reduces side effects and improved complete response rate during radiotherapy: results of a metaanalysis. Int J Radiat Oncol Biol Phys 2006; 64:784-791. This metaanalysis showed a reduction of dysphagia severity with amifostine.
15. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578. This randomized study demonstrated excellent tolerance to cetuximab, a radiation sensitizer.